Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33,051 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Selective CB2 receptor agonists. Part 2: Structure-activity relationship studies and optimization of proline-based compounds.
Riether D, Zindell R, Wu L, Betageri R, Jenkins JE, Khor S, Berry AK, Hickey ER, Ermann M, Albrecht C, Ceci A, Gemkow MJ, Nagaraja NV, Romig H, Sauer A, Thomson DS. Riether D, et al. Among authors: wu l. Bioorg Med Chem Lett. 2015 Feb 1;25(3):581-6. doi: 10.1016/j.bmcl.2014.12.019. Epub 2014 Dec 13. Bioorg Med Chem Lett. 2015. PMID: 25556092
1,4-Diazepane compounds as potent and selective CB2 agonists: optimization of metabolic stability.
Riether D, Wu L, Cirillo PF, Berry A, Walker ER, Ermann M, Noya-Marino B, Jenkins JE, Albaugh D, Albrecht C, Fisher M, Gemkow MJ, Grbic H, Löbbe S, Möller C, O'Shea K, Sauer A, Shih DT, Thomson DS. Riether D, et al. Among authors: wu l. Bioorg Med Chem Lett. 2011 Apr 1;21(7):2011-6. doi: 10.1016/j.bmcl.2011.02.017. Epub 2011 Feb 25. Bioorg Med Chem Lett. 2011. PMID: 21354795
Aryl 1,4-diazepane compounds as potent and selective CB2 agonists: optimization of drug-like properties and target independent parameters.
Zindell R, Walker ER, Scott J, Amouzegh P, Wu L, Ermann M, Thomson D, Fisher MB, Fullenwider CL, Grbic H, Kaplita P, Linehan B, Patel M, Patel M, Löbbe S, Block S, Albrecht C, Gemkow MJ, Shih DT, Riether D. Zindell R, et al. Among authors: wu l. Bioorg Med Chem Lett. 2011 Jul 15;21(14):4276-80. doi: 10.1016/j.bmcl.2011.05.068. Epub 2011 May 27. Bioorg Med Chem Lett. 2011. PMID: 21689933
Selective CB2 receptor agonists. Part 3: the optimization of a piperidine-based series that demonstrated efficacy in an in vivo neuropathic pain model.
Bartolozzi A, Cirillo PF, Berry AK, Hickey ER, Thomson DS, Wu L, Zindell R, Albrecht C, Ceci A, Gemkow MJ, Nagaraja NV, Romig H, Sauer A, Riether D. Bartolozzi A, et al. Among authors: wu l. Bioorg Med Chem Lett. 2015 Feb 1;25(3):587-92. doi: 10.1016/j.bmcl.2014.12.031. Epub 2014 Dec 17. Bioorg Med Chem Lett. 2015. PMID: 25575658
Synthesis, SAR, and series evolution of novel oxadiazole-containing 5-lipoxygenase activating protein inhibitors: discovery of 2-[4-(3-{(r)-1-[4-(2-amino-pyrimidin-5-yl)-phenyl]-1-cyclopropyl-ethyl}-[1,2,4]oxadiazol-5-yl)-pyrazol-1-yl]-N,N-dimethyl-acetamide (BI 665915).
Takahashi H, Riether D, Bartolozzi A, Bosanac T, Berger V, Binetti R, Broadwater J, Chen Z, Crux R, De Lombaert S, Dave R, Dines JA, Fadra-Khan T, Flegg A, Garrigou M, Hao MH, Huber J, Hutzler JM, Kerr S, Kotey A, Liu W, Lo HY, Loke PL, Mahaney PE, Morwick TM, Napier S, Olague A, Pack E, Padyana AK, Thomson DS, Tye H, Wu L, Zindell RM, Abeywardane A, Simpson T. Takahashi H, et al. Among authors: wu l. J Med Chem. 2015 Feb 26;58(4):1669-90. doi: 10.1021/jm501185j. Epub 2015 Feb 11. J Med Chem. 2015. PMID: 25671290
Discovery and optimization of oxadiazole-based FLAP inhibitors.
Bartolozzi A, Abeywardane A, Bosanac T, Broadwater JA, Chen Z, Hutzler JM, Huber JD, Nemoto P, Olague A, Riether D, Simpson T, Takahashi H, Wu L, Zhang Y, Zindell RM. Bartolozzi A, et al. Among authors: wu l. Bioorg Med Chem Lett. 2017 Oct 15;27(20):4652-4659. doi: 10.1016/j.bmcl.2017.09.007. Epub 2017 Sep 8. Bioorg Med Chem Lett. 2017. PMID: 28927794
Discovery of a Series of Pyrazinone RORγ Antagonists and Identification of the Clinical Candidate BI 730357.
Harcken C, Csengery J, Turner M, Wu L, Liang S, Sibley R, Brunette S, Labadia M, Hoyt K, Wayne A, Wieckowski T, Davis G, Panzenbeck M, Souza D, Kugler S, Terenzio D, Collin D, Smith D, Fryer RM, Tseng YC, Hehn JP, Fletcher K, Hughes RO. Harcken C, et al. Among authors: wu l. ACS Med Chem Lett. 2021 Jan 5;12(1):143-154. doi: 10.1021/acsmedchemlett.0c00575. eCollection 2021 Jan 14. ACS Med Chem Lett. 2021. PMID: 33488976 Free PMC article.
New cyclooxygenase-2/5-lipoxygenase inhibitors. 3. 7-tert-butyl-2, 3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: variations at the 5 position.
Janusz JM, Young PA, Ridgeway JM, Scherz MW, Enzweiler K, Wu LI, Gan L, Chen J, Kellstein DE, Green SA, Tulich JL, Rosario-Jansen T, Magrisso IJ, Wehmeyer KR, Kuhlenbeck DL, Eichhold TH, Dobson RL. Janusz JM, et al. Among authors: wu li. J Med Chem. 1998 Aug 27;41(18):3515-29. doi: 10.1021/jm9802416. J Med Chem. 1998. PMID: 9719605
New cyclooxygenase-2/5-lipoxygenase inhibitors. 1. 7-tert-buty1-2,3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: discovery and variation of the 5-keto substituent.
Janusz JM, Young PA, Ridgeway JM, Scherz MW, Enzweiler K, Wu LI, Gan L, Darolia R, Matthews RS, Hennes D, Kellstein DE, Green SA, Tulich JL, Rosario-Jansen T, Magrisso IJ, Wehmeyer KR, Kuhlenbeck DL, Eichhold TH, Dobson RL, Sirko SP, Farmer RW. Janusz JM, et al. Among authors: wu li. J Med Chem. 1998 Mar 26;41(7):1112-23. doi: 10.1021/jm970679q. J Med Chem. 1998. PMID: 9544211
33,051 results
You have reached the last available page of results. Please see the User Guide for more information.